华纳药厂2025年度归母净利润2.41亿元，同比增长46.95%

Core Viewpoint - Warner Pharmaceuticals (688799.SH) reported a revenue of 1.516 billion yuan for the fiscal year 2025, representing a year-on-year growth of 7.26%, and a net profit attributable to the parent company of 241 million yuan, which is an increase of 46.95% [1] Revenue Summary - The revenue growth during the reporting period was primarily driven by increased sales of formulation products, active pharmaceutical ingredients, intermediate products, and growth in technical service income [1] Profit Summary - The increase in net profit attributable to the parent company was significantly influenced by investment income [1] - However, the net profit attributable to the parent company after deducting non-recurring gains and losses declined due to the impact of stock incentive expenses; excluding these expenses, the adjusted net profit was 182 million yuan, reflecting a year-on-year increase of 31.57% [1]